13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 10 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

POM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for POMDOCTOR Ltd (POM), a Consumer Discretionary sector company. POM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 10 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), POMDOCTOR Ltd reports quarterly revenue of $57.2M, net income of $-18.7M, free cash flow of $-21.4M. Top institutional holders of POM by reported 13-F value include CITADEL ADVISORS, XTX Topco Ltd, TWO SIGMA SECURITIES,, based on the most recent SEC filings. POM trades on the Nasdaq exchange and files with the SEC under CIK 1877971. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate POM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for POMDOCTOR Ltd directly from SEC EDGAR.

Revenue

FY 2025

$57.2M

Net Income

FY 2025

$-18.7M

Free Cash Flow

FY 2025

$-21.4M

AI Insight: POM Financial Trends

Insufficient quarterly data to identify financial trends or performance direction.

No quarterly financial statements available for trend analysis.

Obtain quarterly earnings releases or 10-Q filings to establish performance trajectory and margin/growth patterns.

AI Insight: POM Ratio Trends

No ratio data available to assess operational or financial trends.

Insufficient data to evaluate margin, cash flow, or return metrics.

Require income statement, balance sheet, and cash flow data to initiate coverage.

Get alerted when POM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for POMDOCTOR Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put POM on your watchlist

Track score changes the day POMDOCTOR Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is POM a good stock to buy?

13F Pro's AI-powered analysis of POMDOCTOR Ltd (POM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Discretionary sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for POM are available on the POM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own POM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling POM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of POMDOCTOR Ltd's investment landscape.